Pharmaceutical stocks often outperform during market downturns because they pay dividends and their products are mostly ...

AbbVie has a rare dividend track record and impressive innovative abilities. Gilead is a leader in its core market and ...

Johnson & Johnson said on Friday its experimental psoriasis drug met the main goal of a late-stage study, as the once-daily ...

AbbVie’s Skyrizi took home the top spot for most pharma brand ad impressions in April 2025, according to data released by ...

AbbVie is strutting into 2025 like it owns the lab, thanks to a performance cocktail of smart acquisitions, clinical wins, ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

Manufacturing Digital's top 10 biggest pharmaceutical manufacturers delivering innovative healthcare and improved patient ...

AbbVie stands to benefit from a policy change eliminating the “pill penalty” in Medicare’s drug price negotiations, offering ...

AbbVie snagged yet another spot among April’s highest TV ad spenders, as its Vraylar jumped two spots to eighth place with a ...

AbbVie (NYSE:ABBV) recently secured FDA approval for RINVOQ to treat giant cell arteritis, which alongside a biologics license application for TrenibotE, underscored the company's focus on innovation.

Two A+ stocks investors should consider are Alphabet (GOOG) and AbbVie (ABBV). Alphabet is the top mega-cap stock. It posted ...

While AbbVie handily beat expectations this quarter, the company faces declining Humira sales and a challenged aesthetics business, plus the same macro headwinds blowing against the entire industry.